Gongwin Biopharm Holdings Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	37.46	32.04	18.92	1.14	1.14	0.83
Revenue Growth (YoY)	17.94%	69.39%	1554.86%	-	37.21%	235.89%
Cost of Revenue	18.5	23.36	7.72	0.08	0.07	0.05
Gross Profit	18.97	8.68	11.2	1.07	1.08	0.79
Selling, General & Admin	109.3	101.56	91.88	67.43	38.85	41.89
Research & Development	103.95	63.27	52.65	194.32	83.05	76.26
Operating Expenses	212.75	170.74	144.53	261.75	121.9	118.15
Operating Income	-193.78	-162.06	-133.33	-260.68	-120.83	-117.37
Interest Expense	-4.78	-4.3	-7.19	-3.19	-1.18	-0.5
Interest & Investment Income	77.12	64.62	41.61	6.82	2.4	4.6
Currency Exchange Gain (Loss)	1.59	-4.69	-4.85	-39.6	0.9	5.87
Other Non Operating Income (Expenses)	3.33	3.47	2.58	4.51	2.05	1.53
EBT Excluding Unusual Items	-116.53	-102.96	-101.18	-292.13	-116.66	-105.87
Gain (Loss) on Sale of Investments	19.92	11.11	-	-	0.74	4.68
Gain (Loss) on Sale of Assets	-	-0	-	-	-	-
Other Unusual Items	-	-	-	-	1.2	1.87
Pretax Income	-96.61	-91.86	-101.18	-292.13	-114.72	-99.32
Income Tax Expense	0.2	0.13	-	-	15.2	-
Earnings From Continuing Operations	-96.81	-91.99	-101.18	-292.13	-129.92	-99.32
Minority Interest in Earnings	8.43	9.44	9.14	-	8.34	6.25
Net Income	-88.37	-82.55	-92.04	-292.13	-121.58	-93.07
Net Income to Common	-88.37	-82.55	-92.04	-292.13	-121.58	-93.07
Shares Outstanding (Basic)	124	121	113	111	110	104
Shares Outstanding (Diluted)	124	121	113	111	110	104
Shares Change (YoY)	6.00%	6.64%	1.92%	1.44%	4.87%	1.37%
EPS (Basic)	-0.71	-0.68	-0.81	-2.63	-1.11	-0.89
EPS (Diluted)	-0.71	-0.68	-0.81	-2.63	-1.11	-0.89
Free Cash Flow	-111.75	-293.3	-111.7	-239.54	-218.52	-117.4
Free Cash Flow Per Share	-0.90	-2.43	-0.99	-2.15	-2.00	-1.12
Gross Margin	50.63%	27.09%	59.21%	93.26%	94.31%	94.36%
Operating Margin	-517.26%	-505.80%	-704.87%	-22806.74%	-10570.95%	-14089.56%
Profit Margin	-235.90%	-257.64%	-486.58%	-25558.44%	-10637.01%	-11173.11%
Free Cash Flow Margin	-298.31%	-915.41%	-590.55%	-20956.69%	-19118.11%	-14093.16%
EBITDA	-184.82	-153.87	-125.03	-252.2	-112.82	-110.64
D&A For EBITDA	8.96	8.19	8.29	8.48	8	6.72
EBIT	-193.78	-162.06	-133.33	-260.68	-120.83	-117.37

Source: S&P Global Market Intelligence. Standard template. Financial Sources.